Belbuca (Buprenorphine HCl) Patent Expiration, LOE Window & CMS Spending

Belbuca (Buprenorphine HCl) by Biodelivery Sciences International: FDA Orange Book LOE 2032-12-21, 12 AB generics, $202.0M 2024 CMS Part D & Medicaid spend, and 21 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBiodelivery Sciences International
FDA Application & PathwayN207932 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2032-12-21
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors12
2024 CMS Total Public Spend$202.0M
2024 Medicare Part D Spend$160.1M
2024 Medicaid Spend$41.9M
Reported Wholesale Price Change (CA SB 17)21 WAC filings (max 17.4% 2-yr change)